A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

• المؤلفون الرئيسيون: Vishnu Eshwar (مؤلف), Ashwin Kamath (مؤلف), Rajeshwari Shastry (مؤلف), Ashok K. Shenoy (مؤلف), Priyanka Kamath (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2022-11-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...